Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma

<p><strong>Purpose</strong><br/> Our purpose was to describe the patterns and predictors of treatment failure in patients receiving definitive chemoradiation therapy (CRT) for anal squamous cell carcinoma (ASCC), delivered using intensity modulated radiation therapy (IMRT).&l...

Full description

Bibliographic Details
Main Authors: Shakir, R, Adams, R, Cooper, R, Downing, A, Geh, I, Gilbert, D, Jacobs, C, Jones, C, Lorimer, C, Namelo, W, Sebag-Montefiore, D, Shaw, P, Muirhead, R
Format: Journal article
Language:English
Published: Elsevier 2019
_version_ 1826289361555030016
author Shakir, R
Adams, R
Cooper, R
Downing, A
Geh, I
Gilbert, D
Jacobs, C
Jones, C
Lorimer, C
Namelo, W
Sebag-Montefiore, D
Shaw, P
Muirhead, R
author_facet Shakir, R
Adams, R
Cooper, R
Downing, A
Geh, I
Gilbert, D
Jacobs, C
Jones, C
Lorimer, C
Namelo, W
Sebag-Montefiore, D
Shaw, P
Muirhead, R
author_sort Shakir, R
collection OXFORD
description <p><strong>Purpose</strong><br/> Our purpose was to describe the patterns and predictors of treatment failure in patients receiving definitive chemoradiation therapy (CRT) for anal squamous cell carcinoma (ASCC), delivered using intensity modulated radiation therapy (IMRT).</p><br/> <p><strong>Methods and Materials</strong><br/> Our study was a retrospective cohort analysis of consecutive patients treated with curative intent for ASCC using CRT delivered with a standardized IMRT technique in 5 UK cancer centers. Patients were included from the start of UK IMRT guidance from February 2013 to October 31, 2017. Collected data included baseline demographics, treatment details, tumor control, sites of relapse, and overall survival. Statistical analysis to calculate outcomes and predictive factors for outcome measures were performed using SPSS and R.</p><br/> <p><strong>Results</strong><br/> The medical records of 385 consecutive patients were analyzed. Median follow-up was 24.0 months. Within 6 months of completing CRT, 86.7% of patients achieved a complete response. Three-year disease-free survival and overall survival were 75.6% and 85.6%, respectively. Of all relapses, 83.4% occurred at the site of primary disease. There were 2 isolated relapses in regional nodes not involved at outset. Predictive factors for cancer recurrence included male sex, high N-stage, and failure to complete radiation therapy as planned.</p><br/> <p><strong>Conclusions</strong><br/> The treatment results compare favorably to published outcomes from similar cohorts using 3-dimensional conformal CRT. The observed patterns of failure support the current UK IMRT voluming guidelines and dose levels, highlighting our prophylactic nodal dose as sufficient to prevent isolated regional relapse in uninvolved nodes. Further investigation of strategies to optimize CR should remain a priority in ASCC because the site of primary disease remains the overwhelming site of relapse.</p>
first_indexed 2024-03-07T02:27:42Z
format Journal article
id oxford-uuid:a6318659-fd1d-4ea9-a9a1-29454fc5a6b6
institution University of Oxford
language English
last_indexed 2024-03-07T02:27:42Z
publishDate 2019
publisher Elsevier
record_format dspace
spelling oxford-uuid:a6318659-fd1d-4ea9-a9a1-29454fc5a6b62022-03-27T02:45:28ZPatterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinomaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a6318659-fd1d-4ea9-a9a1-29454fc5a6b6EnglishSymplectic Elements at OxfordElsevier2019Shakir, RAdams, RCooper, RDowning, AGeh, IGilbert, DJacobs, CJones, CLorimer, CNamelo, WSebag-Montefiore, DShaw, PMuirhead, R<p><strong>Purpose</strong><br/> Our purpose was to describe the patterns and predictors of treatment failure in patients receiving definitive chemoradiation therapy (CRT) for anal squamous cell carcinoma (ASCC), delivered using intensity modulated radiation therapy (IMRT).</p><br/> <p><strong>Methods and Materials</strong><br/> Our study was a retrospective cohort analysis of consecutive patients treated with curative intent for ASCC using CRT delivered with a standardized IMRT technique in 5 UK cancer centers. Patients were included from the start of UK IMRT guidance from February 2013 to October 31, 2017. Collected data included baseline demographics, treatment details, tumor control, sites of relapse, and overall survival. Statistical analysis to calculate outcomes and predictive factors for outcome measures were performed using SPSS and R.</p><br/> <p><strong>Results</strong><br/> The medical records of 385 consecutive patients were analyzed. Median follow-up was 24.0 months. Within 6 months of completing CRT, 86.7% of patients achieved a complete response. Three-year disease-free survival and overall survival were 75.6% and 85.6%, respectively. Of all relapses, 83.4% occurred at the site of primary disease. There were 2 isolated relapses in regional nodes not involved at outset. Predictive factors for cancer recurrence included male sex, high N-stage, and failure to complete radiation therapy as planned.</p><br/> <p><strong>Conclusions</strong><br/> The treatment results compare favorably to published outcomes from similar cohorts using 3-dimensional conformal CRT. The observed patterns of failure support the current UK IMRT voluming guidelines and dose levels, highlighting our prophylactic nodal dose as sufficient to prevent isolated regional relapse in uninvolved nodes. Further investigation of strategies to optimize CR should remain a priority in ASCC because the site of primary disease remains the overwhelming site of relapse.</p>
spellingShingle Shakir, R
Adams, R
Cooper, R
Downing, A
Geh, I
Gilbert, D
Jacobs, C
Jones, C
Lorimer, C
Namelo, W
Sebag-Montefiore, D
Shaw, P
Muirhead, R
Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma
title Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma
title_full Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma
title_fullStr Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma
title_full_unstemmed Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma
title_short Patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma
title_sort patterns and predictors of relapse following radical chemoradiation therapy delivered using intensity modulated radiation therapy with a simultaneous integrated boost in anal squamous cell carcinoma
work_keys_str_mv AT shakirr patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT adamsr patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT cooperr patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT downinga patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT gehi patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT gilbertd patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT jacobsc patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT jonesc patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT lorimerc patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT namelow patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT sebagmontefiored patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT shawp patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma
AT muirheadr patternsandpredictorsofrelapsefollowingradicalchemoradiationtherapydeliveredusingintensitymodulatedradiationtherapywithasimultaneousintegratedboostinanalsquamouscellcarcinoma